Signet ring cell carcinoma of the ampulla of vater: Report of a case and a review of the literature  by Wakasugi, Masaki et al.
CASE REPORT – OPEN ACCESS
International Journal of Surgery Case Reports 12 (2015) 108–111
Contents lists available at ScienceDirect
International Journal of Surgery Case Reports
journa l homepage: www.caserepor ts .com
Signet ring cell carcinoma of the ampulla of vater: Report of a case
and a review of the literature
Masaki Wakasugia,∗, Masahiro Tanemuraa, Kenta Furukawaa, Maiko Muratab,
Masanori Miyazakib, Masahide Oshitab, Ken-ichi Yoshidac, Hironao Yasuokac,
Hiroki Akamatsua
a Department of Surgery, Osaka Police Hospital, Osaka, Japan
b Department of Internal Medicine, Osaka Police Hospital, Osaka, Japan
c Department of Pathology, Osaka Police Hospital, Osaka, Japan
a r t i c l e i n f o
Article history:
Received 7 May 2015
Received in revised form 22 May 2015
Accepted 24 May 2015
Available online 29 May 2015
Keywords:
Ampulla of vater
Signet ring cell carcinoma
Pancreatoduodenectomy
a b s t r a c t
INTRODUCTION: Signet ring cell carcinoma (SRCC) of the ampulla of vater is a very rare tumor that is
reported infrequently in the literature.
PRESENTATION OF CASE: A 59-year-old woman visited our hospital for evaluation of elevated transam-
inase levels. On laboratory examination of tumor marker levels, carcinoembryonic antigen (CEA) and
carbohydrate antigen (CA) 19–9 levels were normal, and DUPAN-2 was elevated. Computed tomography
(CT) conﬁrmeda2 cm, enhancedmass in theperiampullary region,withmarked commonbile duct dilata-
tion. Endoscopic retrograde cholangiopancreatography (ERCP) showed a swollen papilla of vater, with a
reddish, erosive mucosa. Histological examination of biopsy samples from the ampulla of vater showed
signet ring cell carcinoma (SRCC). The patient underwent radical pancreatoduodenectomy. Pathological
examination showed that the SRCC had inﬁltrated into the duodenal muscularis propria and pancre-
atic parenchyma, and lymph node metastases were identiﬁed around the abdominal aorta and common
hepatic artery. Based on the immunohistochemical staining patterns of the positive results for CDX2 and
MUC2, the tumor cells in thepresent case appeared tohave an intestinal type origin. The ampullary cancer
was diagnosed as T3bN1M1, Stage IV according to the International Union Against Cancer TNM classiﬁ-
cation (UICC). After undergoing adjuvant chemotherapy with cisplatin–gemcitabine chemotherapy for 6
months, the patient has remained disease-free in the 7 months since surgery.
DISCUSSION: SRCC of intestinal-type origin is associated with a favorable outcome.
CONCLUSION: Investigation to conﬁrm the histological origin of SRCC by immunohistochemical staining
might inform the treatment strategy and identify patients with ampullary SRCC who may have a good
prognosis.
© 2015 The Authors. Published by Elsevier Ltd. on behalf of Surgical Associates Ltd. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Most tumors of the ampulla of vater are well-differentiated
adenocarcinomas. Signet ring cell carcinoma (SRCC) at this site
is uncommon [1], and only 26 resected cases have been previ-
ously reported in the English literature. A rare case of a 59-year-old
woman with SRCC and paraaortic lymph node metastases is pre-
sented.
Abbreviations: SRCC, signet ring cell carcinoma; PD, pancreatoduodenectomy;
PPPD, pylorus-preserving pancreatoduodenectomy.
∗ Corresponding author at: Department of Surgery, Osaka Police Hospital, 10-31
Kitayama-cho, Tennouji-ku, Osaka 543-0035, Japan. Tel.: +81 6 6775 6051; fax; +81
6 6775 6051.
E-mail address: wakasugi@oph.gr.jp (M. Wakasugi).
2. Case presentation
A 59-year-old woman visited our hospital for evaluation of
elevated transaminase levels. She had no symptoms, and her
past history was unremarkable. The physical examination ﬁnd-
ings were also unremarkable, with no abdominal tenderness or
palpable masses. Routine laboratory test results were: aspar-
tate aminotransferase (AST) 5 IU/L (normal 10–33 IU/L); alanine
aminotransferase (ALT) 121 IU/L (normal 6–35 IU/L); alkaline phos-
phatase 884 IU/L (normal 120–340 IU/L); -glutamyltransferase
684 IU/L (normal 8–60 IU/L); total bilirubin (T-bil) 0.5mg/dL (nor-
mal 0.4–1.4mg/dL); amylase 87 IU/L (normal 31–106 IU/L); lipase
49 IU/L (normal 8–46 IU/L); and normal inﬂammatory markers.
Laboratory test results for tumor markers were: carcinoembryonic
antigen (CEA) 2.9ng/mL (normal 0–5.0ng/mL); carbohydrate anti-
gen (CA) 19–9 2U/mL (normal 0–37U/mL); DUPAN-2 940U/mL
http://dx.doi.org/10.1016/j.ijscr.2015.05.031
2210-2612/© 2015 The Authors. Published by Elsevier Ltd. on behalf of Surgical Associates Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Fig. 1. Computed tomography: CT scan conﬁrms a 2 cm, enhanced mass in the periampullary region (arrowhead) and shows marked common bile duct dilatation.
(normal 0–150U/mL); and SPAN-1 16U/mL (normal 0–30U/mL).
Abdominal ultrasonography demonstrated gross dilatation of the
common bile and pancreatic ducts. Subsequent computed tomog-
raphy (CT) conﬁrmed a 2 cm, enhanced mass in the periampullary
region, marked common bile duct dilatation, and no evidence of
lymphadenopathy or distant metastases (Fig. 1). Positron emission
tomographywith2 [18 F]-ﬂuoro-2-deoxy-D-glucose (FDG) showed
amasswith an SUVmax of 4.2, consistentwith the CT scan ﬁndings.
Endoscopic retrograde cholangiopancreatography (ERCP) revealed
a swollen papilla of vater with a reddish, erosive mucosa (Fig. 2).
Cholangiography demonstrated an abrupt obstruction of the lower
common bile duct. Histological examination of the biopsy samples
from the ampulla of vater showed SRCC. To decompress the biliary
system, an endoscopic retrospective biliary drainage tube (8.5 Fr)
was inserted before surgery. The patient underwent surgery based
on a diagnosis of SRCC of the ampulla of vater in September 2014.
Surgery revealed no liver metastases or peritoneal dissemination,
and a radical pancreatoduodenectomywasperformed.Microscopic
examination of the ampullary tumor revealed a poorly differenti-
ated adenocarcinoma, of signet ring cell type that inﬁltrated the
duodenal wall and adjacent pancreas (Fig. 3). There was lymphatic
Fig. 2. Endoscopic retrograde cholangiopancreatography: ERCP shows a swollen
papilla of vater with a reddish, erosive mucosa.
and vascular invasion. Lymph node metastases were identiﬁed
around the abdominal aorta and common hepatic artery. Immuno-
histochemical staining was performed, and the signet ring cells
were positive for CK7, CK19, CK20, CDX2, and MUC2, but negative
forMUC5ACandE-cadherin (Fig. 4). Theampullary cancerwasdiag-
nosed as T3bN1M1, Stage IV according to the International Union
Against Cancer TNM classiﬁcation (UICC). After undergoing adju-
vant chemotherapy with cisplatin-gemcitabine chemotherapy for
6 months, the patient has remained disease-free in the 7 months
since surgery.
3. Discussion
Adenocarcinoma of the ampulla of vater is rare, with an inci-
denceof less than6casespermillionpersons annually. It represents
0.2%of all gastrointestinalmalignancies, andaccounts for only6%of
all cancers developing in the periampullary region [1]. SRCC in the
ampulla of vater is extremely uncommon, and in a PubMed search
of the English literature using the key words SRCC and ampulla of
vater; it was found that only 26 such well-documented; resected
cases have been previously described (Table 1) [2–19].
Including the present case, the 26 cases consisted of 12 men
and 14 women. The median age at diagnosis was 61 years (range,
38–83 years). The median tumor diameter was 20mm (mean,
26mm; range, 10–95mm). Six cases had UICC T2 (duodenal inva-
sion) tumors, twelve caseshadT3 (pancreatic invasion) tumors, and
three cases had T4 tumors. Previous reports of ampullary SRCCs
Fig. 3. Microscopic examination: the ampullary tumor is a poorly differentiated
adenocarcinoma of signet ring cell type.
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Fig. 4. Immunohistochemical staining: the signet ring cells and adenocarcinoma cells are positive for CK7 (a), CK19 (b), CK20 (c), CDX2 (d), and MUC2 (e).
were limited to short-term follow-up with a median period of
12 months (mean, 28 months; range, 3–134 months). Long-term
survival, more than 5 years, was documented in only four cases
[9,10,19].
The origin of SRCCs remains controversial. Since they are pre-
dominantly found ingastric cancers, one theory is that these tumors
originate from heterotopic gastric mucosa. Some authors have
reported the presence of ectopic gastricmucosa near the ampullary
tumor [2,7]. Another theory suggests that these carcinomas arise
from areas of gastric-type metaplastic epithelia, which are con-
sidered to be a protective response to elevated acidity and are
observable in the duodenal bulb of peptic ulcer patients [19]. In this
theory, signet ring cells may originate from periampullary duode-
nal heterotopia of an ulcer etiology and expand secondarily to the
ampulla of vater. In the present case, however, no ectopic gastric
epithelium was found in the peritumoral region, and the patient
also had no history of peptic ulcer disease. Immunohistochemi-
cal staining patterns allowing further classiﬁcation of ampullary
SRCC to an intestinal (I)- or pancreatobiliary (PB)-type have been
described [15]. Expression of CK7, along with negativity for CK20,
CDX2, and MUC2, signiﬁes pancreatobiliary-type SRCC, and vice-
versa. Hoedemaeker [20] attempted to classify ampullary SRCC into
Table 1
Resected cases of signet ring cell carcinoma of the ampulla of vater reported in the English literature.
First author Ref. Year Age (y) Sex Size (mm) UICC Treatment Follow-up (months) Outcome
Gardner [2] 1990 69 F 20 T3N0M0 PD NA NA
Hara [3] 2002 68 M 15 T2N0M0 PPPD 10 Alive
Tseng [4] 2002 47 M 20 T3N0M0 PD 6 Alive
Eriguchi [5] 2003 83 M 15 T3N0M0 PD 18 Alive
Li [6] 2004 56 F 15 T2N1M0 PD 12 Alive
Ramia [7] 2004 67 F 18 T2N0M0 PD 12 Alive
Fang [8] 2004 53 M 26 T2N0M0 PD 25 Alive
Bloomston [9] 2005 58 F 10 T2N0M0 PD 134 Alive
Akasu [10] 2007 43 F 20 T2N0M0 PD 90 Alive
Gao [11] 2009 38 F 20 T3N0M0 PD 6 Alive
Ishibashi [12] 2009 59 M 30 T3N0M0 PD 18 died
Gheza [13] 2011 66 M NA NA PD 8 Alive
Paplomata [14] 2011 45 F 30 T4N1Mx PPPD gemcitabine +oxaliplatin 12 Died
Maekawa [15] 2011 75 M 20 T3N0M0 PD 6 Died
Lesquereux-Martínez [16] 2012 78 F 11 TxN1M0 PD gemcitabine 14 Alive
Daoudi [17] 2012 55 M NA T3N0M0 PD gemcitabine + cisplatin 8 Alive
Acharya [18] 2013 78 F 30 T3N0M0 PD 6 Alive
Wen [19] 2014 40 F 30 T3N0M0 PD 8 Alive
Wen [19] 2014 64 F 65 T4NxM0 PD 76 Alive
Wen [19] 2014 75 F 35 T4NxM0 PD 16 Died
Wen [19] 2014 62 M 24 TxN1M0 PD 27 Died
Wen [19] 2014 62 M 30 TxN1M0 PD 9 Died
Wen [19] 2014 53 M 12 T3N0M0 PD 45 Alive
Wen [19] 2014 66 F 15 T3N0M0 PD 54 Alive
Wen [19] 2014 68 M 95 T4NxM0 PD 72 Alive
Our case 2015 59 F 20 T3N1M1 PD gemcitabine + cisplatin 7 Alive
PD: pancreatoduodenectomy.
PPPD: pylorus-preserving pancreatoduodenectomy.
NA: not available.
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the following four types: I, PB, gastric, and mixed type. They con-
cluded that the I-type ampullary SRC patients might have a more
favorableprognosis thanpatientswithPB-typeampullary SRCCdif-
ferentiation. Based on the immunohistochemical staining patterns
showing positive results for CDX2 and MUC2, the tumor cells in the
present case appeared to have an I-type origin, which is associated
with a favorable outcome.
The majority of patients in previous cases of ampullary
SRCC underwent pancreatoduodenectomy (PD), occasionally with
extended lymphadenectomy and/or partial gastrectomy. This radi-
cal approach facilitates lymph node dissection in advanced disease
states, but a pylorus-preserving pancreatoduodenectomy (PPPD),
which has been used in three previous cases of ampullary SRCC
[3,14], may be more applicable in early disease, where curability
is balanced by a more moderate resection. In the present case, a
radical PD with an extensive lymphadenectomy including paraaor-
tic lymph nodes dissection was performed. PPPD was not chosen
in this case because this procedure could result in an insufﬁcient
dissection for the infrapyloric nodes.
Chemoradiotherapy based on 5-ﬂuorouracil has been used as
an adjunctive treatment modality following curative resection
of ampullary adenocarcinomas. However, there is debate as to
whether this actually affords a signiﬁcant survival beneﬁt, since
many patients develop metastatic disease. Presently, no estab-
lished adjuvant chemotherapeutic regimen exists speciﬁcally for
ampullary SRCC, althoughdocumented anti-neoplastic agents have
been used in 4 cases, including the present case [14,16,17]. In the
report of Daoudi et al., a 55-year-old male patient with pT3N0M0
disease received six cycles of adjuvant gemcitabine/cisplatin, with-
out disease recurrence at eight months [17].
4. Conclusions
Conﬁrmation of the histological origin of SRCCby immunohisto-
chemical staining may inform the treatment strategy and identify
patients with ampullary SRCC who may have a good prognosis.
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